EBOS Group Limited has announced that Chemist Warehouse will not be renewing its contract with the company beyond its expiry date of 30 June 2024, resulting in a potential loss of $1.9 billion in revenue annually.
EBOS is developing strategies to minimise the earnings impact and create alternative opportunities for growth, including expanding its pharmacy wholesale services, TerryWhite Chemmart network, medical technology distribution, medical consumables distribution, contract logistics services, pet food and treats brands, and exploring opportunities to expand activities in Southeast Asia.
EBOS has a strong balance sheet with pro forma net debt : EBITDA of approximately 2x as at 31 December 2022.
EBOS Chief Executive Officer, John Cullity, will hold an investor and analyst conference call at 3.00pm (NZT) / 1.00pm (AEST) today.
See more
